A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Public ClinicalTrials.gov record NCT02970318. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia
Study identification
- NCT ID
- NCT02970318
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Acerta Pharma BV
- Industry
- Enrollment
- 310 participants
Conditions and interventions
Conditions
Interventions
- Acalabrutinib (ACP-196) Drug
- Bendamustine Drug
- Idelalisib Drug
- Rituximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 1, 2017
- Primary completion
- Sep 2, 2021
- Completion
- Sep 30, 2027
- Last update posted
- Feb 5, 2026
2017 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Chandler | Arizona | 85224 | — |
| Research Site | Oxnard | California | 93030 | — |
| Research Site | Athens | Georgia | 30607 | — |
| Research Site | Joliet | Illinois | 60435 | — |
| Research Site | Cedar Rapids | Iowa | 52403 | — |
| Research Site | Mount Sterling | Kentucky | 40353 | — |
| Research Site | Saint Cloud | Minnesota | 56303 | — |
| Research Site | Lincoln | Nebraska | 68506 | — |
| Research Site | Brick | New Jersey | 08724 | — |
| Research Site | Nyack | New York | 10960 | — |
| Research Site | Canton | Ohio | 44719 | — |
| Research Site | Fort Sam Houston | Texas | 78234 | — |
| Research Site | Round Rock | Texas | 78665 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 144 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02970318, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02970318 live on ClinicalTrials.gov.